Companion diagnostics have had a profound impact on the way in which cancer is treated – and the promise of truly personalised medicine is edging closer towards reality.
The pace of change is accelerating and while it brings many new opportunities, the ever-increasing complexity also creates multiple challenges – for physicians as well as drug manufacturers.
In this latest paper from the Ipsos Oncology Centre of Excellence, Pieter De Richter – Head of Ipsos’ Molecular Diagnostics (MDx) Portfolio – draws on current data from our Oncology MDx Monitor to show how this complexity can be harnessed to achieve success for all stakeholders, including the patient.
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
When it comes to the fight against cancer, we are on the cusp of a revolution. In this article, Pieter De Richter – Ipsos Healthcare’s Head of Oncology Molecular Diagnostics – explores how cancer treatment will change in the coming decades.